Biohaven Ltd. (NYSE: BHVN)
Health Care · Biotechnology · US
$13.85
+2.59% today · -11.3% 1Y
Biohaven Ltd. (NYSE: BHVN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.09B and employs 274 people.
Over the last twelve months the share price has lost 11.3%, trading between 7.48 and 18.57.
Tweenvest scores Biohaven Ltd. across four factors: quality 12/100. Its strongest factor is quality.
BHVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.09B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.48
- Dividend yield
- —
- Beta (5Y)
- 3.16
- 52-week high
- $18.57
- 52-week low
- $7.48
- Avg volume (3M)
- —
- Shares outstanding
- 151.04M
- Employees
- 274
- Next earnings
- —
About Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
- Founded
- 2022
- Listed since
- Sep 23, 2022
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.